SE430885B - Oxytocin-derivat - Google Patents

Oxytocin-derivat

Info

Publication number: SE430885B
Authority: SE; Sweden
Prior art keywords: oxytocin; derivatives; mpa; tyr; uterine
Prior art date: 1980-03-24

Application number

SE8002222A

Other languages

English (en)

Swedish (sv)

Other versions

SE8002222L (sv

Inventor

P O R Melin

Original Assignee

Ferring Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-24

Filing date

1980-03-24

Publication date

1983-12-19

1980-03-24 Application filed by Ferring Ab filed Critical Ferring Ab

1980-03-24 Priority to SE8002222A priority Critical patent/SE430885B/sv

1981-02-27 Priority to US06/238,715 priority patent/US4402942A/en

1981-03-03 Priority to CH140781A priority patent/CH646139A5/de

1981-03-04 Priority to GB8106843A priority patent/GB2074582B/en

1981-03-05 Priority to DE3108323A priority patent/DE3108323C2/de

1981-03-11 Priority to NL8101191A priority patent/NL8101191A/nl

1981-03-16 Priority to BE0/204141A priority patent/BE887970A/fr

1981-03-23 Priority to JP4227581A priority patent/JPS56150050A/ja

1981-03-23 Priority to FR8105751A priority patent/FR2482093A1/fr

1981-03-24 Priority to IT20684/81A priority patent/IT1136574B/it

1981-09-25 Publication of SE8002222L publication Critical patent/SE8002222L/xx

1983-12-19 Publication of SE430885B publication Critical patent/SE430885B/sv

Links

XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims description 39
229960001723 oxytocin Drugs 0.000 claims description 34
101800000989 Oxytocin Proteins 0.000 claims description 25
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 25
230000008602 contraction Effects 0.000 claims description 12
210000004291 uterus Anatomy 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
208000036029 Uterine contractions during pregnancy Diseases 0.000 claims description 5
230000002269 spontaneous effect Effects 0.000 claims description 5
-1 3-mercaptopropionyl Chemical group 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
229910052739 hydrogen Inorganic materials 0.000 claims 1
239000001257 hydrogen Substances 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
108700042769 prolyl-leucyl-glycine Proteins 0.000 claims 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
102400000050 Oxytocin Human genes 0.000 description 24
230000000694 effects Effects 0.000 description 19
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000000556 agonist Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
241000700159 Rattus Species 0.000 description 7
239000005557 antagonist Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000000243 solution Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000000754 myometrium Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000012891 Ringer solution Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
108010004977 Vasopressins Proteins 0.000 description 2
102000002852 Vasopressins Human genes 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000012173 estrus Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
NDBNSZKHDMXOJE-UHFFFAOYSA-N 3-benzylsulfanylpropanoic acid Chemical compound OC(=O)CCSCC1=CC=CC=C1 NDBNSZKHDMXOJE-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
108010048179 Lypressin Proteins 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
206010046823 Uterine spasm Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
229960003837 lypressin Drugs 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
SLZHLQUFNFXTHB-UHFFFAOYSA-M sodium;5-butan-2-yl-5-ethyl-2-sulfanylidenepyrimidin-3-ide-4,6-dione Chemical compound [Na+].CCC(C)C1(CC)C([O-])=NC(=S)NC1=O SLZHLQUFNFXTHB-UHFFFAOYSA-M 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000003191 uterotonic effect Effects 0.000 description 1
238000011121 vaginal smear Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8002222A 1980-03-24 1980-03-24 Oxytocin-derivat SE430885B (sv)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
SE8002222A SE430885B (sv)	1980-03-24	1980-03-24	Oxytocin-derivat
US06/238,715 US4402942A (en)	1980-03-24	1981-02-27	Oxytocin derivatives
CH140781A CH646139A5 (de)	1980-03-24	1981-03-03	Oxytocin-derivate.
GB8106843A GB2074582B (en)	1980-03-24	1981-03-04	Oxytocin-derivatives
DE3108323A DE3108323C2 (de)	1980-03-24	1981-03-05	1-Desamino (2-O-alkyltyrosin)-oxytocine und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
NL8101191A NL8101191A (nl)	1980-03-24	1981-03-11	Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus.
BE0/204141A BE887970A (fr)	1980-03-24	1981-03-16	Nouveaux derives d'ocytocine et compositions pharmaceutiques contenant ces derives
JP4227581A JPS56150050A (en)	1980-03-24	1981-03-23	Oxitocin derivative
FR8105751A FR2482093A1 (fr)	1980-03-24	1981-03-23	Nouveaux derives d'ocytocine et compositions pharmaceutiques contenant ces derives
IT20684/81A IT1136574B (it)	1980-03-24	1981-03-24	Derivati della ossitocina

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8002222A SE430885B (sv)	1980-03-24	1980-03-24	Oxytocin-derivat

Publications (2)

Publication Number	Publication Date
SE8002222L SE8002222L (sv)	1981-09-25
SE430885B true SE430885B (sv)	1983-12-19

Family

ID=20340577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8002222A SE430885B (sv)	1980-03-24	1980-03-24	Oxytocin-derivat

Country Status (10)

Country	Link
US (1)	US4402942A (it)
JP (1)	JPS56150050A (it)
BE (1)	BE887970A (it)
CH (1)	CH646139A5 (it)
DE (1)	DE3108323C2 (it)
FR (1)	FR2482093A1 (it)
GB (1)	GB2074582B (it)
IT (1)	IT1136574B (it)
NL (1)	NL8101191A (it)
SE (1)	SE430885B (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8207277L (sv) *	1982-12-21	1984-06-22	Ferring Ab	Vasotocin-derivat
US4504469A (en) *	1982-12-21	1985-03-12	Ferring Ab	Vasotocin derivatives
US4483794A (en) *	1983-05-10	1984-11-20	Ceskoslovenska Akademie Ved	Analogs of neurohypophysial hormones
US4624943A (en) *	1985-03-20	1986-11-25	Smithkline Beckman Corporation	Aromatic basic-tailed vasopressin antagonists
US5225528A (en) *	1990-02-27	1993-07-06	Merck & Co., Inc.	Cyclic hexapeptide oxytocin antagonists
DE4042008A1 (de) *	1990-12-22	1992-06-25	Schering Ag	Vasopressin-derivate
US5830848A (en) *	1992-10-09	1998-11-03	The Regents Of The University Of California	Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
RU2125062C1 (ru) *	1997-04-10	1999-01-20	Государственный научный центр вирусологии и биотехнологии "Вектор"	Защищенные производные окситоцина
US6933417B1 (en)	1999-11-22	2005-08-23	Dow Global Technologies Inc.	Process for vinyl chloride manufacture from ethane and ethylene with partial CHl recovery from reactor effluent
US6797845B1 (en)	1999-11-22	2004-09-28	Dow Global Technologies Inc.	Process for vinyl chloride manufacture from ethane and ethylene with immediate HCl recovery from reactor effluent
US6909024B1 (en) *	1999-11-22	2005-06-21	The Dow Chemical Company	Process for the conversion of ethylene to vinyl chloride and novel catalyst compositions useful for such process
US6680415B1 (en) *	1999-11-22	2004-01-20	Dow Global Technologies Inc.	Oxyhalogenation process using catalyst having porous rare earth halide support
SE0100684D0 (sv) *	2001-02-28	2001-02-28	Kerstin Uvnaes Moberg	New subject-matter
CN100424056C (zh) *	2001-05-23	2008-10-08	陶氏环球技术公司	C3+烃的氧化卤化和任选脱氢反应
US20040152929A1 (en) *	2002-05-08	2004-08-05	Clarke William D	Process for vinyl chloride manufacture from ethane and ethylene with air feed and alternative hcl processing methods
US7722733B2 (en)	2004-03-29	2010-05-25	Baxter International Inc.	Method for sterile connection of tubing
TWI463990B (zh) *	2009-09-21	2014-12-11	Ferring Bv	催產素受體促進劑
AU2015338717B2 (en)	2014-10-31	2018-12-20	Glaxosmithkline Intellectual Property Development Limited	Powder formulation
SG10202009723PA (en)	2016-01-04	2020-11-27	ObsEva SA	Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2018015497A2 (en)	2016-07-21	2018-01-25	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2020137880A1 (ja) *	2018-12-27	2020-07-02	国立大学法人北海道大学	オキシトシン誘導体及びその使用
US20220323410A1 (en)	2019-09-03	2022-10-13	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh)	2020-02-10	2022-11-22	奥布赛瓦股份公司	用于催产素受体拮抗剂疗法的生物标志物
US20240024294A1 (en)	2020-11-16	2024-01-25	Xoma (Us) Llc	Compositions and methods for the treatment or prevention of preterm labor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1463865A (fr) *	1964-07-27	1966-07-22	Ceskoslovenska Akademie Ved	Procédé pour la préparation des dérivés cycliques de peptides ainsi que les produits conformes à ceux obtenus par le présent procédé ou procédé similaire
CS194980B1 (en) *	1976-07-16	1979-12-31	Joseph H Cort	Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle

1980
- 1980-03-24 SE SE8002222A patent/SE430885B/sv not_active IP Right Cessation
1981
- 1981-02-27 US US06/238,715 patent/US4402942A/en not_active Expired - Fee Related
- 1981-03-03 CH CH140781A patent/CH646139A5/de not_active IP Right Cessation
- 1981-03-04 GB GB8106843A patent/GB2074582B/en not_active Expired
- 1981-03-05 DE DE3108323A patent/DE3108323C2/de not_active Expired
- 1981-03-11 NL NL8101191A patent/NL8101191A/nl not_active Application Discontinuation
- 1981-03-16 BE BE0/204141A patent/BE887970A/fr not_active IP Right Cessation
- 1981-03-23 JP JP4227581A patent/JPS56150050A/ja active Pending
- 1981-03-23 FR FR8105751A patent/FR2482093A1/fr active Granted
- 1981-03-24 IT IT20684/81A patent/IT1136574B/it active

Also Published As

Publication number	Publication date
DE3108323A1 (de)	1981-12-24
GB2074582B (en)	1983-07-06
DE3108323C2 (de)	1983-11-24
CH646139A5 (de)	1984-11-15
US4402942A (en)	1983-09-06
FR2482093A1 (fr)	1981-11-13
GB2074582A (en)	1981-11-04
IT8120684A0 (it)	1981-03-24
JPS56150050A (en)	1981-11-20
SE8002222L (sv)	1981-09-25
BE887970A (fr)	1981-07-16
FR2482093B1 (it)	1984-11-09
NL8101191A (nl)	1981-10-16
IT1136574B (it)	1986-09-03

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8002222-1

Effective date: 19890426

Format of ref document f/p: F

Publication	Publication Date	Title
US4402942A (en)	1983-09-06	Oxytocin derivatives
CA2189250C (en)	2000-08-01	Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
EP0679092B1 (en)	1999-04-28	Cytokine restraining agents
Melin et al.	1986	Synthetic antagonists of the myometrial response to vasopressin and oxytocin
US5763404A (en)	1998-06-09	Methods for using LHRH antagonists with low histamine release
US5786332A (en)	1998-07-28	Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
EP0112809B1 (en)	1986-05-28	Vasotocin derivatives
US5480869A (en)	1996-01-02	Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
IE840867L (en)	1984-10-14	Peptides
CA2068312A1 (en)	1991-05-12	Agent for neutralising the procoagulant activity associated with tumor cells
Melin et al.	1981	Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity
CA2072253A1 (en)	1991-07-10	Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
KR100291304B1 (ko)	2001-06-01	옥시토신 길항제
KR102417762B1 (ko)	2022-07-06	펜타펩타이드 및 그 용도
IE912378A1 (en)	1992-01-15	Derivatives of pituitary posterior lobe hormones
US4956344A (en)	1990-09-11	Method for treatment of lesions in the large intestinal epithelium with a tripeptide
EP0394283B1 (en)	1992-12-02	Use of a tripeptide for the preparation of pharmaceutical compositions and a pharmaceutical composition and method
JPS6267100A (ja)	1987-03-26	バソプレシン化合物
SU1083560A1 (ru)	1986-01-30	Гептапептид,обладающий способностью ингибировать миотропное действие брадикинина
AU703402C (en)	1999-12-16	Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
AU678329C (en)	1999-03-11	Cytokine restraining agents
Freer et al.	1980	Organ selective angiotensin antagonists: sarcosyl1-cysteinyl (S-methyl) 8-angiotensin I
WO1992011287A1 (de)	1992-07-09	Vasopressin- und vasotocin-derivate
CZ993A3 (en)	1993-07-14	derivatives of neurohypophysis lobe hormones